Abstract:Background: A pivotal impetus has driven the development of numerous small molecules aiming to improve therapeutic strategies for type 2 diabetes. Glucokinase (GK) activation has been offered a new realm of therapeutic antidiabetic activity with novel heter-ocyclic derivatives. In the context of antidiabetic drug design, GK is an interesting and newly validated target. A key enzyme needed for blood glucose homeostasis is Glucokinase, which is dysfunctional in individuals with type 2 diabetes. Heterocyclic derivatives are utilized in this innovative approach to activate GK enzymes as medicinal agents that will significantly improve type 2 diabetes management. Objective: To address type 2 diabetes, as well as minimize unwanted side effects, this research endeavor aimed to develop activators of glucokinase. Methods: A rigorous scrutiny was conducted of the Maybridge online repository, which houses a formidable collection of 53,000 lead compounds. A collection of 125 compounds that contain the thiazolidinedione core was selected from this extensive collection. The struc-tures were generated using ChemDraw 2D, stabilized conformation with ChemBioDraw Ul-tra, and docked using Auto Dock Vina 1.5.6 in this methodology. In addition, log P was pre-dicted online using the Swiss ADME algorithm. The PKCSM software was used to predict the toxicity of the leading compounds. Results: The highest binding affinity was found for AS72 and AS108 to GK receptors. GI absorption and excretion of these compounds were efficient due to Lipinski's Rule of Five compliance. When compared with the standard drugs Dorzagliatin (GKA) and MRK (co-crys-tallized ligand), these substances demonstrated a notable lack of AMES toxicity, skin sensiti-zation, and hepatotoxicity. Conclusion: In recent studies, lead molecules that possess enhanced pharmacokinetic profiles, increased binding affinity, and lower toxicity were developed to act as glucokinase activators.

Development of sodium glucose co-transporter 2 (SGLT2) inhibitors with novel structure by molecular docking and dynamics simulation

Insight into the Interaction Mechanism of Human SGLT2 with Its Inhibitors: 3D-QSAR Studies, Homology Modeling, and Molecular Docking and Molecular Dynamics Simulations

A selectivity study of sodium-dependent glucose cotransporter 2/sodium-dependent glucose cotransporter 1 inhibitors by molecular modeling.

Exploring Novel Lead Scaffolds for SGLT2 Inhibitors: Insights from Machine Learning and Molecular Dynamics Simulations.

Progress in Sodium-glucose Co-transporter-2 Inhibitors: the New Target for Treatment of Type 2 Diabetes

Combined Hqsar, Topomer Comfa, Homology Modeling And Docking Studies On Triazole Derivatives As Sglt2 Inhibitors

A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors

In-silico screening and identification of glycomimetic as potential human sodium-glucose co-transporter 2 inhibitor

Synthesis, Crystal structure, Spectral analysis, DFT calculations, Docking studies, in vitro biological activity evaluation and in silico drug-likeness prediction of a novel L-xylose derivative

QSAR studies on triazole derivatives as sglt inhibitors via CoMFA and CoMSIA

In silico discovery of potential sodium–glucose cotransporter-2 inhibitors from natural products for treatment of heart failure via molecular docking and molecular dynamics simulation approach

Structural Mechanism of SGLT1 Inhibitors

Exploring sodium glucose cotransporter (SGLT2) inhibitors with machine learning approach: A novel hope in anti-diabetes drug discovery

Synthesis and Biological Evaluation of 6-Hydroxyl C-aryl Glucoside Derivatives As Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors

Structure-based molecular docking and molecular dynamics simulations study for the identification of dipeptidyl peptidase 4 inhibitors in type 2 diabetes.

Computer-assisted Identification of Novel Small Molecule Inhibitors Targeting GLUT1

Structural basis of inhibition of the human SGLT2–MAP17 glucose transporter

Novel α‐glucosidase Inhibitors Designed as Type 2 Diabetes Drugs by QSAR, Molecular Docking and Molecular Dynamics Simulation Methods

Identification of Novel Inhibitors Targeting SGK1 via Ensemble-Based Virtual Screening Method, Biological Evaluation and Molecular Dynamics Simulation

Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes.

Molecular Docking, Pharmacophore Modeling, and ADMET Prediction of Novel Heterocyclic Leads as Glucokinase Activators